Dr. Patrick Soon-Shiong
Billionaire biotech entrepreneur Patrick Soon-Shiong is expanding his company's relationship with Sorrento Therapeutics, promising $110 million in cash and equity in exchange for the rights to some cancer-fighting immunotherapies.
NantHealth, an arm of billionaire physician and biotech entrepreneur Patrick Soon-Shiong's empire, promises to improve cancer diagnostics through a marriage of genomics and high-speed computing. But behind its sleek marketing campaign and Soon-Shiong's bravura, the company is misleading customers and putting patients at risk, according to a lawsuit filed by two former employees.
Billionaire physician and biotech entrepreneur Patrick Soon-Shiong has launched a company devoted to immuno-oncology, licensing a treatment from Amgen to get rolling in the field.
Patrick Soon-Shiong, billionaire physician and biotech entrepreneur, wants in on the hottest field in oncology, forming a joint venture with Sorrento Therapeutics to develop therapies that harness the body's immune system to fight cancer.
Dr. Patrick Soon-Shiong has teamed up with the University of Oxford and others to further the United Kingdom's plan to build the "NASA of biomedicine." Some of the £141 million ($227 million) investment is earmarked for establishing computing infrastructure to support the U.K.'s genomics project.
In science, there's a 10-year horizon for major innovations to come to fruition, biotech billionaire Patrick Soon-Shiong said, and while that timeline may not jibe with the expectations of many investors, success in the field demands patience.
Billionaire Patrick Soon-Shiong is working to marry Big Data and cancer treatment, and his old friends at Celgene have again stepped in to help out, investing $25 million in NantHealth, a cloud-based oncology brain trust.
Biotech billionaire Patrick Soon-Shiong is back to doing cancer drug deals. And he's working with some very familiar partners at Celgene to build up a new platform for nanoparticle albumin-bound drugs--building on the same tumor-targeting tech used for Abraxane.
They are already rich, so why spotlight billionaires like Microsoft Chairman Bill Gates and Teva Chairman Dr. Phillip Frost? Well, the mega-wealthy have made an impact all over the biopharma world,...
The biotech field is covered with startup efforts with cancer drugs, but when Dr. Patrick Soon-Shiong announces one the business world stops and listens.